Basilea Pharmaceutica AG
BPMUF
$77.40
$11.9018.17%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.03% | 5.28% | 5.93% | 24.59% | 51.70% |
| Total Other Revenue | 129.39% | 159.94% | 196.77% | 230.18% | 313.69% |
| Total Revenue | 13.25% | 18.42% | 18.49% | 35.94% | 62.20% |
| Cost of Revenue | 29.84% | 34.96% | 33.69% | 17.80% | 3.77% |
| Gross Profit | -5.94% | -1.31% | -0.45% | 73.02% | 365.71% |
| SG&A Expenses | 15.81% | 20.83% | 19.60% | 13.98% | 9.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.93% | 32.01% | 30.72% | 17.02% | 4.83% |
| Operating Income | -15.34% | -11.48% | -10.46% | 138.66% | 1,229.08% |
| Income Before Tax | -12.06% | -13.93% | -19.29% | 158.70% | 621.25% |
| Income Tax Expenses | 2,158.58% | 174.34% | 134.39% | 118.39% | 97.48% |
| Earnings from Continuing Operations | -21.84% | -32.58% | -44.74% | 49.64% | 9,803.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.84% | -32.58% | -44.74% | 49.64% | 9,803.52% |
| EBIT | -15.34% | -11.48% | -10.46% | 138.66% | 1,229.08% |
| EBITDA | -15.50% | -11.05% | -9.31% | 129.28% | 1,838.31% |
| EPS Basic | -23.00% | -33.57% | -45.45% | 48.80% | 8,632.55% |
| Normalized Basic EPS | -13.75% | -14.85% | -19.29% | 160.15% | 618.68% |
| EPS Diluted | -20.77% | -31.04% | -42.63% | 56.54% | 2,372.16% |
| Normalized Diluted EPS | -12.54% | -11.03% | -15.46% | 184.46% | 539.03% |
| Average Basic Shares Outstanding | 1.12% | 1.31% | 1.37% | 1.25% | 1.14% |
| Average Diluted Shares Outstanding | 0.92% | -2.00% | -1.88% | 2.33% | 6.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |